Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Evaluation of ifosfamide for treatment of various canine neoplasms.

Tytuł :
Evaluation of ifosfamide for treatment of various canine neoplasms.
Autorzy :
Rassnick KM; Harrington Oncology Program, School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA. />Frimberger AE
Wood CA
Williams LE
Cotter SM
Moore AS
Pokaż więcej
Źródło :
Journal of veterinary internal medicine [J Vet Intern Med] 2000 May-Jun; Vol. 14 (3), pp. 271-6.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: <2010-> : Malden, MA : Wiley Periodicals
Original Publication: Philadelphia : J.B. Lippincott Co., [c1987-
MeSH Terms :
Antineoplastic Agents, Alkylating/*therapeutic use
Dog Diseases/*drug therapy
Ifosfamide/*therapeutic use
Lymphoma/*veterinary
Sarcoma/*veterinary
Animals ; Dog Diseases/mortality ; Dogs ; Female ; Lymphoma/drug therapy ; Lymphoma/mortality ; Male ; Massachusetts/epidemiology ; Records/veterinary ; Retrospective Studies ; Sarcoma/drug therapy ; Sarcoma/mortality ; Survival Analysis ; Treatment Outcome
Substance Nomenclature :
0 (Antineoplastic Agents, Alkylating)
UM20QQM95Y (Ifosfamide)
Entry Date(s) :
Date Created: 20000601 Date Completed: 20000921 Latest Revision: 20190513
Update Code :
20210210
DOI :
10.1892/0891-6640(2000)014<0271:eoifto>2.3.co;2
PMID :
10830540
Czasopismo naukowe
lfosfamide (3-[2-chloroethyl]-2[(2 chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) is an alkylating agent with a broad spectrum of antitumor activity. The efficacy and toxicity of ifosfamide were evaluated in 72 dogs with spontaneously occurring tumors. Forty dogs (56%) had lymphoma, 31 (43%) had sarcomas, and 1 had a metastatic carcinoma. Five dogs received ifosfamide at dosages <350 mg/m2 IV. Neither toxicity nor response were observed, and the remaining dogs received ifosfamide at 350 mg/m2 (n = 18) and 375 mg/m2 body surface area IV (n = 49). Saline diuresis and the thiol compound mesna were used to prevent urothelial toxicity. Fifty-two dogs had measurable tumors and could be evaluated for response. Complete responses were seen in 1 dog with metastatic leiomyosarcoma of the urinary bladder and in 1 dog with metastatic cutaneous hemangiosarcoma. One dog with lymphoma had a partial response for 112 days. Six dogs with splenic hemangiosarcoma received ifosfamide postsplenectomy and their median survival time was 147 days. The acute dose limiting toxicity was neutropenia 7 days after administration of ifosfamide. The median and mean neutrophil counts 7 days after ifosfamide at 350 mg/m2 were 2,035 cells/microL and 4,773 cells/microL, respectively (n = 12). The median and mean neutrophil counts 7 days after ifosfamide at 375 mg/m2 were 2,500 cells/microL and 3,594 cells/microL, respectively (n = 37). No dog developed clinical or microscopic evidence of hemorrhagic cystitis. Ifosfamide appears safe to use in tumor-bearing dogs, and the evaluation of combination chemotherapy protocols that include ifosfamide should be considered.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies